Cardiac Marker Testing Market by Product, Biomarker (Troponin, CK-MB, BNP, hs-CRP, Myoglobin), Technology (Chemiluminescence, ELISA), Indication (MI, CHF, Atherosclerosis), Assay Format (Singleplex, Multiplex), Point of Testing - Global Forecast to 2031

1 INTRODUCTION 35 1.1 STUDY OBJECTIVES 35 1.2 MARKET DEFINITION 35 1.3 STUDY SCOPE 36 1.3.1 MARKETS COVERED & REGIONAL SCOPE 36 1.3.2 INCLUSIONS & EXCLUSIONS 37 1.3.3 YEARS CONSIDERED 38 1.4 CURRENCY CONSIDERED 38 1.5 STAKEHOLDERS 38 1.6 SUMMARY OF CHANGES 39 2 EXECUTIVE SUMMARY 40 2.1 KEY INSIGHTS & MARKET HIGHLIGHTS 40 2.2 KEY MARKET PARTICIPANTS: SHARE INSIGHTS & STRATEGIC DEVELOPMENTS 41 2.3 DISRUPTIVE TRENDS SHAPING MARKET GROWTH 42 2.4 HIGH-GROWTH SEGMENTS & EMERGING FRONTIERS 43 2.5 SNAPSHOT: GLOBAL MARKET SIZE, GROWTH RATE, AND FORECAST 44 3 PREMIUM INSIGHTS 45 3.1 CARDIAC MARKER TESTING MARKET OVERVIEW 45 3.2 CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2026 VS. 2031 45 3.3 CARDIAC MARKER TESTING MARKET, BY TECHNOLOGY, 2026 VS. 2031 46 3.4 CARDIAC MARKER TESTING MARKET, BY INDICATION, 2026 VS. 2031 46 3.5 CARDIAC MARKER TESTING MARKET, BY BIOMARKER TYPE, 2026 VS. 2031 47 3.6 CARDIAC MARKER TESTING MARKET, BY POINT OF TESTING, 2026 VS. 2031 47 3.7 CARDIAC MARKER TESTING MARKET, BY ASSAY FORMAT, 2026 VS. 2031 48 3.8 CARDIAC MARKER TESTING MARKET, BY END USER, 2026 VS. 2031 48 3.9 CARDIAC MARKER TESTING MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 49 4 MARKET OVERVIEW 50 4.1 INTRODUCTION 50 4.2 MARKET DYNAMICS 50 4.2.1 DRIVERS 51 4.2.1.1 Rising prevalence of cardiovascular diseases 51 4.2.1.2 Increasing geriatric population and subsequent rise in heart conditions worldwide 51 4.2.1.3 Rising clinical studies for identification of novel cardiac biomarkers 52 4.2.1.4 Growing demand for PoC testing 52   4.2.2 RESTRAINTS 53 4.2.2.1 Technical issues related to sample collection and storage 53 4.2.2.2 Unfavorable regulatory processes and limited reimbursement structure 53 4.2.3 OPPORTUNITIES 54 4.2.3.1 Ongoing research on novel cardiac biomarkers for cardiovascular diseases 54 4.2.3.2 Emerging markets 54 4.2.4 CHALLENGES 55 4.2.4.1 Challenges associated with biomarker assay validation 55 4.3 UNMET NEEDS & WHITE SPACES 55 4.3.1 UNMET NEEDS IN CARDIAC MARKER TESTING MARKET 55 4.3.2 WHITE SPACE OPPORTUNITIES 56 4.4 INTERCONNECTED MARKETS & CROSS-SECTOR OPPORTUNITIES 56 4.4.1 INTERCONNECTED MARKETS 56 4.4.2 CROSS-SECTOR OPPORTUNITIES 57 4.5 STRATEGIC MOVES BY TIER 1/2/3 PLAYERS 58 4.5.1 KEY MOVES & STRATEGIC FOCUS 58 5 INDUSTRY TRENDS 59 5.1 PORTER’S FIVE FORCES ANALYSIS 59 5.1.1 THREAT OF NEW ENTRANTS 60 5.1.2 THREAT OF SUBSTITUTES 60 5.1.3 BARGAINING POWER OF BUYERS 61 5.1.4 BARGAINING POWER OF SUPPLIERS 61 5.1.5 INTENSITY OF COMPETITIVE RIVALRY 61 5.2 MACROECONOMIC INDICATORS 61 5.2.1 INTRODUCTION 61 5.2.2 GDP TRENDS & FORECAST 62 5.3 SUPPLY CHAIN ANALYSIS 64 5.4 VALUE CHAIN ANALYSIS 65 5.5 ECOSYSTEM ANALYSIS 67 5.6 PRICING ANALYSIS 68 5.6.1 AVERAGE SELLING PRICE OF CARDIAC MARKER TESTING PRODUCTS, BY TYPE, 2024–2026 68 5.6.2 AVERAGE SELLING PRICE OF CARDIAC MARKER TESTING PRODUCTS, BY KEY PLAYER, 2024–2026 69 5.6.3 AVERAGE SELLING PRICE OF CARDIAC MARKER TESTING PRODUCTS, BY REGION, 2024–2026 69 5.7 TRADE ANALYSIS 70 5.7.1 IMPORT SCENARIO (HS CODE 3822) 70 5.7.2 EXPORT SCENARIO (HS CODE 3822) 71 5.8 KEY CONFERENCES & EVENTS, 2026–2027 71 5.9 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 72 5.10 INVESTMENT & FUNDING SCENARIO 73 5.11 CASE STUDY ANALYSIS 74 5.11.1 CASE STUDY 1: IMPLEMENTATION OF HIGH-SENSITIVITY TROPONIN (HS-CTN) ASSAYS FOR RAPID MYOCARDIAL INFARCTION DIAGNOSIS 74 5.11.2 CASE STUDY 2: USE OF BNP/NT-PROBNP TESTING FOR HEART FAILURE DIAGNOSIS AND MANAGEMENT 74 5.11.3 CASE STUDY 3: USE OF HIGH-SENSITIVITY TROPONIN FOR LONG-TERM CARDIOVASCULAR RISK PREDICTION IN GENERAL POPULATION 75 5.12 IMPACT OF 2025 US TARIFFS ON CARDIAC MARKER TESTING MARKET 75 5.12.1 INTRODUCTION 75 5.12.2 KEY TARIFF RATES 76 5.12.3 PRICE IMPACT ANALYSIS 76 5.12.4 IMPACT ON REGION 77 5.12.4.1 North America 77 5.12.4.2 Europe 77 5.12.4.3 Asia Pacific 77 5.12.5 IMPACT ON END-USE INDUSTRIES 78 5.12.5.1 Hospital laboratories 78 5.12.5.2 Reference laboratories 78 5.12.5.3 Contract testing laboratories 78 5.12.5.4 Academic institutes 78 6 TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, PATENTS, INNOVATIONS, AND FUTURE APPLICATIONS 79 6.1 KEY EMERGING TECHNOLOGIES 79 6.1.1 CHEMILUMINESCENCE IMMUNOASSAYS (CLIA) 79 6.1.2 IMMUNOFLUORESCENCE ASSAYS (IFA) 79 6.1.3 ENZYME-LINKED IMMUNOSORBENT ASSAYS (ELISA) 80 6.1.4 LATERAL FLOW ASSAYS 80 6.2 COMPLEMENTARY TECHNOLOGIES 80 6.2.1 POC IMMUNOANALYZERS 80 6.2.2 DIGITAL IMMUNOASSAY PLATFORMS 80 6.3 TECHNOLOGY/PRODUCT ROADMAP 81 6.4 PATENT ANALYSIS 82 6.4.1 LIST OF MAJOR PATENTS 83 6.4.2 LIST OF KEY PATENTS 83 6.5 FUTURE APPLICATIONS 84 6.6 IMPACT OF AI/GENERATIVE AI ON CARDIAC MARKER TESTING MARKET 84 6.6.1 INTRODUCTION 84 6.6.2 TOP USE CASES & MARKET POTENTIAL 85 6.6.3 KEY COMPANIES IMPLEMENTING AI 86 6.6.4 FUTURE OF AI 86 7 SUSTAINABILITY & REGULATORY LANDSCAPE 87 7.1 REGIONAL REGULATIONS & COMPLIANCE 87 7.1.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 87 7.2 SUSTAINABILITY INITIATIVES 89 7.2.1 ENVIRONMENTAL IMPACT AND ECO-FRIENDLY INITIATIVES IN CARDIAC MARKER TESTING PRODUCTS 89 7.2.1.1 Eco-friendly Initiatives 89 7.3 SUSTAINABILITY IMPACT & REGULATORY POLICY INITIATIVES 90 8 CUSTOMER LANDSCAPE & BUYER BEHAVIOR 91 8.1 DECISION-MAKING PROCESS 91 8.2 BUYER STAKEHOLDERS & BUYING EVALUATION CRITERIA 91 8.2.1 KEY STAKEHOLDERS IN BUYING PROCESS 91 8.2.2 BUYING CRITERIA 92 8.3 ADOPTION BARRIERS & INTERNAL CHALLENGES 92 8.4 UNMET NEEDS IN VARIOUS END-USE INDUSTRIES 94 8.5 MARKET PROFITABILITY 95 8.5.1 REVENUE POTENTIAL 95 8.5.2 COST DYNAMICS 95 8.5.3 MARGIN OPPORTUNITIES IN KEY APPLICATIONS 96 9 CARDIAC MARKER TESTING MARKET, BY PRODUCT 97 9.1 INTRODUCTION 98 9.2 REAGENTS & KITS 98 9.2.1 RISING VOLUME OF DIAGNOSTIC TESTS TO DRIVE DEMAND FOR REAGENTS & KITS 98 9.3 INSTRUMENTS 101 9.3.1 EXPANDING DIAGNOSTIC INFRASTRUCTURE TO DRIVE MARKET GROWTH 101 10 CARDIAC MARKER TESTING MARKET, BY TECHNOLOGY 105 10.1 INTRODUCTION 106 10.2 IMMUN0ASSAYS 106 10.2.1 CHEMILUMINESCENCE 109 10.2.1.1 High sensitivity, wide linear range, and good specificity to aid market growth 109 10.2.2 IMMUNOFLUORESCENCE 112 10.2.2.1 Advancements in fluorescence technologies to drive immunofluorescence adoption 112 10.2.3 LATERAL FLOW IMMUNOASSAYS 114 10.2.3.1 Increasing use in point-of-care settings to propel adoption 114   10.2.4 ELISA 117 10.2.4.1 Long shelf life and ease of use to propel growth 117 10.3 CLINICAL CHEMISTRY 119 10.3.1 COST-EFFECTIVENESS AND HIGH-THROUGHPUT TESTING TO SUSTAIN GROWTH IN CLINICAL CHEMISTRY MARKET 119 11 CARDIAC MARKER TESTING MARKET, BY INDICATION 123 11.1 INTRODUCTION 124 11.2 MYOCARDIAL INFARCTION 124 11.2.1 RISING MYOCARDIAL INFARCTION BURDEN AND NEED FOR EARLY DIAGNOSIS TO DRIVE CARDIAC MARKER TESTING DEMAND 124 11.3 CONGESTIVE HEART FAILURE 126 11.3.1 INCREASING USE OF MULTIMARKER TESTING TO SUPPORT MARKET GROWTH 126 11.4 ACUTE CORONARY SYNDROME 129 11.4.1 INCREASING INCIDENCE OF RISK FACTORS ASSOCIATED WITH ACS TO DRIVE ADOPTION OF CARDIAC MARKERS 129 11.5 ATHEROSCLEROSIS 131 11.5.1 HIGH PREVALENCE OF ATHEROSCLEROSIS TO DRIVE MARKET 131 11.6 ISCHEMIA 134 11.6.1 INCREASE IN CARDIAC ISCHEMIA TO BOOST DEMAND FOR CARDIAC MARKER TESTS 134 12 CARDIAC MARKER TESTING MARKET, BY BIOMARKER TYPE 138 12.1 INTRODUCTION 139 12.2 TROPONIN I & T 139 12.2.1 HIGH SENSITIVITY AND SPECIFICITY IN DETECTION OF CVD TO DRIVE MARKET 139 12.3 CREATININE KINASE-MB 142 12.3.1 POOR SPECIFICITY AND BRIEF ELEVATION DURATION TO HAMPER MARKET GROWTH 142 12.4 BRAIN NATRIURETIC PEPTIDE 144 12.4.1 USE OF BNP WITH OTHER CARDIAC MARKERS TO ENHANCE UTILIZATION 144 12.5 MYOGLOBIN 147 12.5.1 GROWING USE TO ASSESS PATIENTS WITH CHEST PAIN IN EMERGENCY DEPARTMENT SETTINGS TO BOOST GROWTH 147 12.6 HOMOCYSTEINE 150 12.6.1 RISK STRATIFICATION AND LONG-TERM CARDIOVASCULAR RISK ASSESSMENT TO DRIVE MARKET GROWTH 150 12.7 HIGH-SENSITIVITY C-REACTIVE PROTEIN 153 12.7.1 INCREASING INCIDENCE OF CARDIOVASCULAR DISEASES TO PROPEL ADOPTION 153 12.8 OTHER CARDIAC BIOMARKERS 155   13 CARDIAC MARKER TESTING MARKET VOLUME ANALYSIS, BY BIOMARKER TYPE (NUMBER OF TESTS) 159 14 CARDIAC MARKER TESTING MARKET, BY POINT OF TESTING 165 14.1 INTRODUCTION 166 14.2 LAB TESTS 166 14.2.1 HIGH-SENSITIVITY, AUTOMATION, AND FLEXIBLE PROCUREMENT MODELS TO DRIVE LAB-BASED TESTING DOMINANCE 166 14.3 POC TESTS 169 14.3.1 RISING DEMAND FOR DECENTRALIZED HEALTHCARE SERVICES TO DRIVE MARKET 169 15 CARDIAC MARKER TESTING MARKET, BY ASSAY FORMAT 172 15.1 INTRODUCTION 173 15.2 SINGLEPLEX ASSAYS 173 15.2.1 HIGH ACCURACY AND OPERATIONAL SIMPLICITY TO SUSTAIN SINGLEPLEX ASSAY DOMINANCE 173 15.3 MULTIPLEX ASSAYS 175 15.3.1 COMPREHENSIVE MULTI-BIOMARKER DETECTION AND RAPID DIAGNOSIS TO DRIVE MULTIPLEX ASSAY GROWTH 175 16 CARDIAC MARKER TESTING MARKET, BY END USER 179 16.1 INTRODUCTION 180 16.2 LABORATORY TESTING FACILITIES 180 16.2.1 HOSPITAL LABORATORIES 183 16.2.1.1 Growing focus on healthcare system to stimulate growth 183 16.2.2 REFERENCE LABORATORIES 186 16.2.2.1 Rising outsourcing and advanced testing capabilities to position reference laboratories as key growth drivers 186 16.2.3 CONTRACT TESTING LABORATORIES 189 16.2.3.1 Outsourced expertise and scalable testing capabilities to boost role of contract laboratories 189 16.3 ACADEMIC INSTITUTES 191 16.3.1 CONTINUOUS RESEARCH & DEVELOPMENT OF NOVEL BIOMARKERS TO DRIVE MARKET 191 16.4 POINT-OF-CARE TESTING 194 16.4.1 EARLY DETECTION AND LOWER TURNAROUND TIME TO BOOST MARKET 194 17 CARDIAC MARKER TESTING MARKET, BY REGION 197 17.1 INTRODUCTION 198 17.2 NORTH AMERICA 199 17.2.1 US 203 17.2.1.1 Growing support from NIH for development of novel cardiac biomarkers to drive market 203 17.2.2 CANADA 207 17.2.2.1 Government initiatives to support market growth 207 17.3 EUROPE 211 17.3.1 GERMANY 215 17.3.1.1 Stringent regulations for food, pharmaceutical, and medical device industries to fuel growth 215 17.3.2 UK 219 17.3.2.1 Increasing cardiovascular patient volume to spur growth 219 17.3.3 FRANCE 222 17.3.3.1 Highly advanced and well-established healthcare system to drive demand for market 222 17.3.4 ITALY 226 17.3.4.1 Growing geriatric population and improved life expectancy to support market growth 226 17.3.5 SPAIN 230 17.3.5.1 Government efforts to improve health infrastructure to fuel demand 230 17.3.6 REST OF EUROPE 234 17.4 ASIA PACIFIC 238 17.4.1 JAPAN 243 17.4.1.1 Growing geriatric population and increasing incidence of chronic diseases to drive market 243 17.4.2 CHINA 247 17.4.2.1 Rising number of hospitals and increasing healthcare expenditure to boost adoption 247 17.4.3 INDIA 251 17.4.3.1 Infrastructural improvements to support growth 251 17.4.4 AUSTRALIA 255 17.4.4.1 Higher government healthcare expenditure to support market growth 255 17.4.5 SOUTH KOREA 258 17.4.5.1 Country’s fast-aging demographic to drive market 258 17.4.6 REST OF ASIA PACIFIC 262 17.5 LATIN AMERICA 265 17.5.1 BRAZIL 269 17.5.1.1 Rising government support to boost adoption of market 269 17.5.2 MEXICO 273 17.5.2.1 Rising geriatric population to support market growth 273 17.5.3 REST OF LATIN AMERICA 277 17.6 MIDDLE EAST & AFRICA 280   18 COMPETITIVE LANDSCAPE 285 18.1 INTRODUCTION 285 18.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 285 18.2.1 OVERVIEW OF STRATEGIES DEPLOYED BY PLAYERS IN CARDIAC MARKER TESTING MARKET 285 18.3 REVENUE ANALYSIS, 2023–2025 287 18.4 MARKET SHARE ANALYSIS, 2025 288 18.4.1 GLOBAL MARKET SHARE ANALYSIS, 2025 288 18.4.2 US MARKET SHARE ANALYSIS, 2025 290 18.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2025 290 18.5.1 STARS 290 18.5.2 EMERGING LEADERS 290 18.5.3 PERVASIVE PLAYERS 291 18.5.4 PARTICIPANTS 291 18.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2025 292 18.5.5.1 Company footprint 292 18.5.5.2 Region footprint 292 18.5.5.3 Product footprint 293 18.5.5.4 Technology footprint 293 18.5.5.5 Point of testing footprint 294 18.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025 294 18.6.1 PROGRESSIVE COMPANIES 294 18.6.2 RESPONSIVE COMPANIES 294 18.6.3 DYNAMIC COMPANIES 294 18.6.4 STARTING BLOCKS 295 18.6.5 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025 296 18.6.5.1 Detailed list of key startups/SMEs 296 18.6.5.2 Competitive benchmarking of startups/SMEs (1/2) 296 18.6.5.3 Competitive benchmarking of startups/SMEs (2/2) 297 18.7 COMPANY VALUATION & FINANCIAL METRICS 297 18.7.1 FINANCIAL METRICS 297 18.7.2 COMPANY VALUATION 298 18.8 BRAND/PRODUCT COMPARISON 299 18.9 COMPETITIVE SCENARIO 300 18.9.1 PRODUCT APPROVALS 300 18.9.2 DEALS 300   19 COMPANY PROFILES 302 19.1 KEY PLAYERS 302 19.1.1 F. HOFFMANN-LA ROCHE AG 302 19.1.1.1 Business overview 302 19.1.1.2 Products offered 303 19.1.1.3 Recent developments 305 19.1.1.3.1 Product approvals 305 19.1.1.3.2 Deals 305 19.1.1.4 MnM view 305 19.1.1.4.1 Key strengths 305 19.1.1.4.2 Strategic choices 306 19.1.1.4.3 Weaknesses & competitive threats 306 19.1.2 ABBOTT LABORATORIES 307 19.1.2.1 Business overview 307 19.1.2.2 Products offered 308 19.1.2.3 MnM view 309 19.1.2.3.1 Key strengths 309 19.1.2.3.2 Strategic choices 309 19.1.2.3.3 Weaknesses & competitive threats 309 19.1.3 DANAHER CORPORATION 310 19.1.3.1 Business overview 310 19.1.3.2 Products offered 311 19.1.3.3 MnM view 312 19.1.3.3.1 Key strengths 312 19.1.3.3.2 Strategic choices 312 19.1.3.3.3 Weaknesses & competitive threats 312 19.1.4 SIEMENS HEALTHINEERS AG 313 19.1.4.1 Business overview 313 19.1.4.2 Products offered 314 19.1.4.3 MnM view 315 19.1.4.3.1 Key strengths 315 19.1.4.3.2 Strategic choices 315 19.1.4.3.3 Weaknesses & competitive threats 316 19.1.5 THERMO FISHER SCIENTIFIC 317 19.1.5.1 Business overview 317 19.1.5.2 Products offered 318 19.1.5.3 MnM view 319 19.1.5.3.1 Key strengths 319 19.1.5.3.2 Strategic choices 319 19.1.5.3.3 Weaknesses & competitive threats 319   19.1.6 BIO-RAD LABORATORIES 320 19.1.6.1 Business overview 320 19.1.6.2 Products offered 321 19.1.7 BIOMÉRIEUX SA 322 19.1.7.1 Business overview 322 19.1.7.2 Products offered 323 19.1.7.3 Recent developments 324 19.1.7.3.1 Deals 324 19.1.8 BECTON, DICKINSON AND COMPANY 325 19.1.8.1 Business overview 325 19.1.8.2 Products offered 326 19.1.9 DIASORIN SPA 327 19.1.9.1 Business overview 327 19.1.9.2 Products offered 328 19.1.10 REVVITY 329 19.1.10.1 Business overview 329 19.1.10.2 Products offered 331 19.1.11 TOSOH CORPORATION 332 19.1.11.1 Business overview 332 19.1.11.2 Products offered 333 19.1.12 QUIDEL CORPORATION 335 19.1.12.1 Business overview 335 19.1.12.2 Products offered 336 19.1.12.3 Recent developments 337 19.1.12.3.1 Product approvals 337 19.1.12.3.2 Deals 337 19.2 OTHER PLAYERS 338 19.2.1 LSI MEDIENCE CORPORATION (PHC HOLDINGS CORPORATION) 338 19.2.2 RANDOX LABORATORIES 339 19.2.3 GUANGZHOU WONDFO BIOTECH CO., LTD. 340 19.2.4 BODITECH MED INC. 341 19.2.5 BTNX INC. 342 19.2.6 RESPONSE BIOMEDICAL 343 19.2.7 ALFA SCIENTIFIC DESIGNS, INC. 344 19.2.8 CTK BIOTECH 345 19.2.9 CREATIVE DIAGNOSTICS 346 19.2.10 LIFESIGN LLC 347 19.2.11 DIASYS DIAGNOSTIC SYSTEMS GMBH 348 19.2.12 ATLAS MEDICAL GMBH 349 19.2.13 GETEIN BIOTECH INC. 350   20 RESEARCH METHODOLOGY 351 20.1 RESEARCH DATA 351 20.1.1 SECONDARY DATA 352 20.1.1.1 List of secondary sources 352 20.1.1.2 Key data from secondary sources 353 20.1.2 PRIMARY DATA 353 20.1.2.1 List of primary sources 354 20.1.2.2 Key data from primary sources 354 20.1.2.3 Key industry insights 356 20.1.2.4 Breakdown of primary interviews 357 20.2 MARKET SIZE ESTIMATION 357 20.2.1 TOTAL MARKET SIZE: CARDIAC MARKER TESTING MARKET 357 20.2.2 BOTTOM-UP APPROACH 357 20.2.2.1 Approach 1: Revenue estimation of key players 358 20.2.2.2 Approach 2: Study of annual reports and investor presentations 358 20.2.2.3 Approach 3: Primary interviews 358 20.2.2.4 Growth forecast 358 20.2.2.5 CAGR projections 359 20.2.3 TOP-DOWN APPROACH 359 20.3 DATA TRIANGULATION 360 20.4 RESEARCH ASSUMPTIONS 361 20.4.1 STUDY-RELATED ASSUMPTIONS 361 20.4.2 GROWTH RATE ASSUMPTIONS 362 20.5 RESEARCH LIMITATIONS 362 20.6 RISK ASSESSMENT 363 21 APPENDIX 364 21.1 DISCUSSION GUIDE 364 21.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 368 21.3 CUSTOMIZATION OPTIONS 370 21.4 RELATED REPORTS 370 21.5 AUTHOR DETAILS 371

TABLE 1 CARDIAC MARKER TESTING MARKET: IMPACT OF PORTER’S FORCES 60 TABLE 2 GDP PERCENTAGE CHANGE (%), BY KEY COUNTRY, 2023–2030 62 TABLE 3 NORTH AMERICA: MACROECONOMIC INDICATORS 63 TABLE 4 EUROPE: MACROECONOMIC INDICATORS 63 TABLE 5 ASIA PACIFIC: MACROECONOMIC INDICATORS 63 TABLE 6 LATIN AMERICA: MACROECONOMIC INDICATORS 64 TABLE 7 MIDDLE EAST & AFRICA: MACROECONOMIC INDICATORS 64 TABLE 8 CARDIAC MARKER TESTING MARKET: ROLE OF COMPANIES IN ECOSYSTEM 68 TABLE 9 AVERAGE SELLING PRICING OF CARDIAC MARKER TESTING PRODUCTS, BY TYPE, 2024–2026 (USD) 68 TABLE 10 AVERAGE SELLING PRICE OF CARDIAC MARKER TESTING PRODUCTS, BY KEY PLAYER, 2024–2026 (USD) 69 TABLE 11 AVERAGE SELLING PRICE OF CARDIAC MARKER TESTING PRODUCTS, BY REGION, 2024–2026 (USD) 70 TABLE 12 IMPORT DATA FOR HS CODE 3822 DIAGNOSTIC KITS & REAGENTS, BY COUNTRY, 2021–2025 (USD MILLION) 70 TABLE 13 EXPORT DATA FOR HS CODE 3822 DIAGNOSTIC KITS & REAGENTS, BY COUNTRY, 2021–2025 (USD MILLION) 71 TABLE 14 CARDIAC MARKER TESTING MARKET: KEY CONFERENCES & EVENTS, 2026–2027 71 TABLE 15 US-ADJUSTED RECIPROCAL TARIFF RATES 76 TABLE 16 KEY PATENTS IN CARDIAC MARKER TESTING MARKET, 2022–2026 83 TABLE 17 KEY COMPANIES IMPLEMENTING AI IN CARDIAC MARKER TESTING MARKET 86 TABLE 18 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 87 TABLE 19 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 87 TABLE 20 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 88 TABLE 21 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 88 TABLE 22 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 88 TABLE 23 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY END USER (%) 91 TABLE 24 KEY BUYING CRITERIA, BY END USER 92 TABLE 25 ADOPTION BARRIERS & INTERNAL CHALLENGES 93 TABLE 26 CARDIAC MARKER TESTING MARKET: UNMET NEEDS IN VARIOUS END-USE INDUSTRIES 94 TABLE 27 CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 98 TABLE 28 SOME KEY COMPANIES PROVIDING CARDIAC MARKER TESTING REAGENTS & KITS 99 TABLE 29 CARDIAC MARKER TESTING REAGENTS & KITS MARKET, BY REGION, 2024–2031 (USD MILLION) 99 TABLE 30 NORTH AMERICA: CARDIAC MARKER TESTING REAGENTS & KITS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 100 TABLE 31 EUROPE: CARDIAC MARKER TESTING REAGENTS & KITS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 100 TABLE 32 ASIA PACIFIC: CARDIAC MARKER TESTING REAGENTS & KITS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 101 TABLE 33 LATIN AMERICA: CARDIAC MARKER TESTING REAGENTS & KITS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 101 TABLE 34 SOME KEY COMPANIES PROVIDING CARDIAC MARKER TESTING INSTRUMENTS 102 TABLE 35 CARDIAC MARKER TESTING INSTRUMENTS MARKET, BY REGION, 2024–2031 (USD MILLION) 102 TABLE 36 NORTH AMERICA: CARDIAC MARKER TESTING INSTRUMENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 103 TABLE 37 EUROPE: CARDIAC MARKER TESTING INSTRUMENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 103 TABLE 38 ASIA PACIFIC: CARDIAC MARKER TESTING INSTRUMENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 104 TABLE 39 LATIN AMERICA: CARDIAC MARKER TESTING INSTRUMENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 104 TABLE 40 CARDIAC MARKER TESTING MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 106 TABLE 41 CARDIAC MARKER TESTING MARKET FOR IMMUNOASSAYS, BY TYPE, 2024–2031 (USD MILLION) 107 TABLE 42 CARDIAC MARKER TESTING MARKET FOR IMMUNOASSAYS, BY REGION, 2024–2031 (USD MILLION) 107 TABLE 43 NORTH AMERICA: CARDIAC MARKER TESTING MARKET FOR IMMUNOASSAYS, BY COUNTRY, 2024–2031 (USD MILLION) 107 TABLE 44 EUROPE: CARDIAC MARKER TESTING MARKET FOR IMMUNOASSAYS, BY COUNTRY, 2024–2031 (USD MILLION) 108 TABLE 45 ASIA PACIFIC: CARDIAC MARKER TESTING MARKET FOR IMMUNOASSAYS, BY COUNTRY, 2024–2031 (USD MILLION) 108 TABLE 46 LATIN AMERICA: CARDIAC MARKER TESTING MARKET FOR IMMUNOASSAYS, BY COUNTRY, 2024–2031 (USD MILLION) 109 TABLE 47 CARDIAC MARKER TESTING MARKET FOR CHEMILUMINESCENCE, BY REGION, 2024–2031 (USD MILLION) 110 TABLE 48 NORTH AMERICA: CARDIAC MARKER TESTING MARKET FOR CHEMILUMINESCENCE, BY COUNTRY, 2024–2031 (USD MILLION) 110 TABLE 49 EUROPE: CARDIAC MARKER TESTING MARKET FOR CHEMILUMINESCENCE, BY COUNTRY, 2024–2031 (USD MILLION) 111 TABLE 50 ASIA PACIFIC: CARDIAC MARKER TESTING MARKET FOR CHEMILUMINESCENCE, BY COUNTRY, 2024–2031 (USD MILLION) 111 TABLE 51 LATIN AMERICA: CARDIAC MARKER TESTING MARKET FOR CHEMILUMINESCENCE, BY COUNTRY, 2024–2031 (USD MILLION) 112 TABLE 52 CARDIAC MARKER TESTING MARKET FOR IMMUNOFLUORESCENCE, BY REGION, 2024–2031 (USD MILLION) 113 TABLE 53 NORTH AMERICA: CARDIAC MARKER TESTING MARKET FOR IMMUNOFLUORESCENCE, BY COUNTRY, 2024–2031 (USD MILLION) 113 TABLE 54 EUROPE: CARDIAC MARKER TESTING MARKET FOR IMMUNOFLUORESCENCE, BY COUNTRY, 2024–2031 (USD MILLION) 113 TABLE 55 ASIA PACIFIC: CARDIAC MARKER TESTING MARKET FOR IMMUNOFLUORESCENCE, BY COUNTRY, 2024–2031 (USD MILLION) 114 TABLE 56 LATIN AMERICA: CARDIAC MARKER TESTING MARKET FOR IMMUNOFLUORESCENCE, BY COUNTRY, 2024–2031 (USD MILLION) 114 TABLE 57 CARDIAC MARKER TESTING MARKET FOR LATERAL FLOW IMMUNOASSAYS, BY REGION, 2024–2031 (USD MILLION) 115 TABLE 58 NORTH AMERICA: CARDIAC MARKER TESTING MARKET FOR LATERAL FLOW IMMUNOASSAYS, BY COUNTRY, 2024–2031 (USD MILLION) 115 TABLE 59 EUROPE: CARDIAC MARKER TESTING MARKET FOR LATERAL FLOW IMMUNOASSAYS, BY COUNTRY, 2024–2031 (USD MILLION) 116 TABLE 60 ASIA PACIFIC: CARDIAC MARKER TESTING MARKET FOR LATERAL FLOW IMMUNOASSAYS, BY COUNTRY, 2024–2031 (USD MILLION) 116 TABLE 61 LATIN AMERICA: CARDIAC MARKER TESTING MARKET FOR LATERAL FLOW IMMUNOASSAYS, BY COUNTRY, 2024–2031 (USD MILLION) 117 TABLE 62 CARDIAC MARKER TESTING MARKET FOR ELISA, BY REGION, 2024–2031 (USD MILLION) 118 TABLE 63 NORTH AMERICA: CARDIAC MARKER TESTING MARKET FOR ELISA, BY COUNTRY, 2024–2031 (USD MILLION) 118 TABLE 64 EUROPE: CARDIAC MARKER TESTING MARKET FOR ELISA, BY COUNTRY, 2024–2031 (USD MILLION) 118 TABLE 65 ASIA PACIFIC: CARDIAC MARKER TESTING MARKET FOR ELISA, BY COUNTRY, 2024–2031 (USD MILLION) 119 TABLE 66 LATIN AMERICA: CARDIAC MARKER TESTING MARKET FOR ELISA, BY COUNTRY, 2024–2031 (USD MILLION) 119 TABLE 67 CARDIAC MARKER TESTING MARKET FOR CLINICAL CHEMISTRY, BY REGION, 2024–2031 (USD MILLION) 120 TABLE 68 NORTH AMERICA: CARDIAC MARKER TESTING MARKET FOR CLINICAL CHEMISTRY, BY COUNTRY, 2024–2031 (USD MILLION) 120 TABLE 69 EUROPE: CARDIAC MARKER TESTING MARKET FOR CLINICAL CHEMISTRY, BY COUNTRY, 2024–2031 (USD MILLION) 121 TABLE 70 ASIA PACIFIC: CARDIAC MARKER TESTING MARKET FOR CLINICAL CHEMISTRY, BY COUNTRY, 2024–2031 (USD MILLION) 121 TABLE 71 LATIN AMERICA: CARDIAC MARKER TESTING MARKET FOR CLINICAL CHEMISTRY, BY COUNTRY, 2024–2031 (USD MILLION) 122 TABLE 72 CARDIAC MARKER TESTING MARKET, BY INDICATION, 2024–2031 (USD MILLION) 124 TABLE 73 CARDIAC MARKER TESTING MARKET FOR MYOCARDIAL INFARCTION, BY REGION, 2024–2031 (USD MILLION) 125 TABLE 74 NORTH AMERICA: CARDIAC MARKER TESTING MARKET FOR MYOCARDIAL INFARCTION, BY COUNTRY, 2024–2031 (USD MILLION) 125 TABLE 75 EUROPE: CARDIAC MARKER TESTING MARKET FOR MYOCARDIAL INFARCTION, BY COUNTRY, 2024–2031 (USD MILLION) 125 TABLE 76 ASIA PACIFIC: CARDIAC MARKER TESTING MARKET FOR MYOCARDIAL INFARCTION, BY COUNTRY, 2024–2031 (USD MILLION) 126 TABLE 77 LATIN AMERICA: CARDIAC MARKER TESTING MARKET FOR MYOCARDIAL INFARCTION, BY COUNTRY, 2024–2031 (USD MILLION) 126 TABLE 78 CARDIAC MARKER TESTING MARKET FOR CONGESTIVE HEART FAILURE, BY REGION, 2024–2031 (USD MILLION) 127 TABLE 79 NORTH AMERICA: CARDIAC MARKER TESTING MARKET FOR CONGESTIVE HEART FAILURE , BY COUNTRY, 2024–2031 (USD MILLION) 127 TABLE 80 EUROPE: CARDIAC MARKER TESTING MARKET FOR CONGESTIVE HEART FAILURE, BY COUNTRY, 2024–2031 (USD MILLION) 128 TABLE 81 ASIA PACIFIC: CARDIAC MARKER TESTING MARKET FOR CONGESTIVE HEART FAILURE, BY COUNTRY, 2024–2031 (USD MILLION) 128 TABLE 82 LATIN AMERICA: CARDIAC MARKER TESTING MARKET FOR CONGESTIVE HEART FAILURE, BY COUNTRY, 2024–2031 (USD MILLION) 129 TABLE 83 CARDIAC MARKER TESTING MARKET FOR ACUTE CORONARY SYNDROME, BY REGION, 2024–2031 (USD MILLION) 130 TABLE 84 NORTH AMERICA: CARDIAC MARKER TESTING MARKET FOR ACUTE CORONARY SYNDROME, BY COUNTRY, 2024–2031 (USD MILLION) 130 TABLE 85 EUROPE: CARDIAC MARKER TESTING MARKET FOR ACUTE CORONARY SYNDROME, BY COUNTRY, 2024–2031 (USD MILLION) 130 TABLE 86 ASIA PACIFIC: CARDIAC MARKER TESTING MARKET FOR ACUTE CORONARY SYNDROME, BY COUNTRY, 2024–2031 (USD MILLION) 131 TABLE 87 LATIN AMERICA: CARDIAC MARKER TESTING MARKET FOR ACUTE CORONARY SYNDROME, BY COUNTRY, 2024–2031 (USD MILLION) 131 TABLE 88 CARDIAC MARKER TESTING MARKET FOR ATHEROSCLEROSIS, BY REGION, 2024–2031 (USD MILLION) 132 TABLE 89 NORTH AMERICA: CARDIAC MARKER TESTING MARKET FOR ATHEROSCLEROSIS, BY COUNTRY, 2024–2031 (USD MILLION) 132 TABLE 90 EUROPE: CARDIAC MARKER TESTING MARKET FOR ATHEROSCLEROSIS, BY COUNTRY, 2024–2031 (USD MILLION) 133 TABLE 91 ASIA PACIFIC: CARDIAC MARKER TESTING MARKET FOR ATHEROSCLEROSIS, BY COUNTRY, 2024–2031 (USD MILLION) 133 TABLE 92 LATIN AMERICA: CARDIAC MARKER TESTING MARKET FOR ATHEROSCLEROSIS, BY COUNTRY, 2024–2031 (USD MILLION) 134 TABLE 93 CARDIAC MARKER TESTING MARKET FOR ISCHEMIA, BY REGION, 2024–2031 (USD MILLION) 135 TABLE 94 NORTH AMERICA: CARDIAC MARKER TESTING MARKET FOR ISCHEMIA, BY COUNTRY, 2024–2031 (USD MILLION) 135 TABLE 95 EUROPE: CARDIAC MARKER TESTING MARKET FOR ISCHEMIA, BY COUNTRY, 2024–2031 (USD MILLION) 136 TABLE 96 ASIA PACIFIC: CARDIAC MARKER TESTING MARKET FOR ISCHEMIA, BY COUNTRY, 2024–2031 (USD MILLION) 136 TABLE 97 LATIN AMERICA: CARDIAC MARKER TESTING MARKET FOR ISCHEMIA, BY COUNTRY, 2024–2031 (USD MILLION) 137 TABLE 98 CARDIAC MARKER TESTING MARKET, BY BIOMARKER TYPE, 2024–2031 (USD MILLION) 139 TABLE 99 CARDIAC MARKER TESTING MARKET FOR TROPONIN I & T, BY REGION, 2024–2031 (USD MILLION) 140 TABLE 100 NORTH AMERICA: CARDIAC MARKER TESTING MARKET FOR TROPONIN I & T, BY COUNTRY, 2024–2031 (USD MILLION) 140 TABLE 101 EUROPE: CARDIAC MARKER TESTING MARKET FOR TROPONIN I & T, BY COUNTRY, 2024–2031 (USD MILLION) 141 TABLE 102 ASIA PACIFIC: CARDIAC MARKER TESTING MARKET FOR TROPONIN I & T, BY COUNTRY, 2024–2031 (USD MILLION) 141 TABLE 103 LATIN AMERICA: CARDIAC MARKER TESTING MARKET FOR TROPONIN I & T, BY COUNTRY, 2024–2031 (USD MILLION) 142 TABLE 104 CARDIAC MARKER TESTING MARKET FOR CREATININE KINASE-MB, BY REGION, 2024–2031 (USD MILLION) 143 TABLE 105 NORTH AMERICA: CARDIAC MARKER TESTING MARKET FOR CREATININE KINASE-MB, BY COUNTRY, 2024–2031 (USD MILLION) 143 TABLE 106 EUROPE: CARDIAC MARKER TESTING MARKET FOR CREATININE KINASE-MB, BY COUNTRY, 2024–2031 (USD MILLION) 143 TABLE 107 ASIA PACIFIC: CARDIAC MARKER TESTING MARKET FOR CREATININE KINASE-MB, BY COUNTRY, 2024–2031 (USD MILLION) 144 TABLE 108 LATIN AMERICA: CARDIAC MARKER TESTING MARKET FOR CREATININE KINASE-MB, BY COUNTRY, 2024–2031 (USD MILLION) 144 TABLE 109 CARDIAC MARKER TESTING MARKET FOR BRAIN NATRIURETIC PEPTIDE, BY REGION, 2024–2031 (USD MILLION) 145 TABLE 110 NORTH AMERICA: CARDIAC MARKER TESTING MARKET FOR BRAIN NATRIURETIC PEPTIDE, BY COUNTRY, 2024–2031 (USD MILLION) 145 TABLE 111 EUROPE: CARDIAC MARKER TESTING MARKET FOR BRAIN NATRIURETIC PEPTIDE, BY COUNTRY, 2024–2031 (USD MILLION) 146 TABLE 112 ASIA PACIFIC: CARDIAC MARKER TESTING MARKET FOR BRAIN NATRIURETIC PEPTIDE, BY COUNTRY, 2024–2031 (USD MILLION) 146 TABLE 113 LATIN AMERICA: CARDIAC MARKER TESTING MARKET FOR BRAIN NATRIURETIC PEPTIDE, BY COUNTRY, 2024–2031 (USD MILLION) 147 TABLE 114 CARDIAC MARKER TESTING MARKET FOR MYOGLOBIN, BY REGION, 2024–2031 (USD MILLION) 148 TABLE 115 NORTH AMERICA: CARDIAC MARKER TESTING MARKET FOR MYOGLOBIN, BY COUNTRY, 2024–2031 (USD MILLION) 148 TABLE 116 EUROPE: CARDIAC MARKER TESTING MARKET FOR MYOGLOBIN, BY COUNTRY, 2024–2031 (USD MILLION) 149 TABLE 117 ASIA PACIFIC: CARDIAC MARKER TESTING MARKET FOR MYOGLOBIN, BY COUNTRY, 2024–2031 (USD MILLION) 149 TABLE 118 LATIN AMERICA: CARDIAC MARKER TESTING MARKET FOR MYOGLOBIN, BY COUNTRY, 2024–2031 (USD MILLION) 150 TABLE 119 CARDIAC MARKER TESTING MARKET FOR HOMOCYSTEINE, BY REGION, 2024–2031 (USD MILLION) 151 TABLE 120 NORTH AMERICA: CARDIAC MARKER TESTING MARKET FOR HOMOCYSTEINE, BY COUNTRY, 2024–2031 (USD MILLION) 151 TABLE 121 EUROPE: CARDIAC MARKER TESTING MARKET FOR HOMOCYSTEINE, BY COUNTRY, 2024–2031 (USD MILLION) 152 TABLE 122 ASIA PACIFIC: CARDIAC MARKER TESTING MARKET FOR HOMOCYSTEINE, BY COUNTRY, 2024–2031 (USD MILLION) 152 TABLE 123 LATIN AMERICA: CARDIAC MARKER TESTING MARKET FOR HOMOCYSTEINE, BY COUNTRY, 2024–2031 (USD MILLION) 153 TABLE 124 CARDIAC MARKER TESTING MARKET FOR HIGH-SENSITIVITY C-REACTIVE PROTEIN, BY REGION, 2024–2031 (USD MILLION) 153 TABLE 125 NORTH AMERICA: CARDIAC MARKER TESTING MARKET FOR HIGH-SENSITIVITY C-REACTIVE PROTEIN, BY COUNTRY, 2024–2031 (USD MILLION) 154 TABLE 126 EUROPE: CARDIAC MARKER TESTING MARKET FOR HIGH-SENSITIVITY C-REACTIVE PROTEIN, BY COUNTRY, 2024–2031 (USD MILLION) 154 TABLE 127 ASIA PACIFIC: CARDIAC MARKER TESTING MARKET FOR HIGH-SENSITIVITY C-REACTIVE PROTEIN, BY COUNTRY, 2024–2031 (USD MILLION) 155 TABLE 128 LATIN AMERICA: CARDIAC MARKER TESTING MARKET FOR HIGH-SENSITIVITY C-REACTIVE PROTEIN, BY COUNTRY, 2024–2031 (USD MILLION) 155 TABLE 129 CARDIAC MARKER TESTING MARKET FOR OTHER CARDIAC BIOMARKERS, BY REGION, 2024–2031 (USD MILLION) 156 TABLE 130 NORTH AMERICA: CARDIAC MARKER TESTING MARKET FOR OTHER CARDIAC BIOMARKERS, BY COUNTRY, 2024–2031 (USD MILLION) 156 TABLE 131 EUROPE: CARDIAC MARKER TESTING MARKET FOR OTHER CARDIAC BIOMARKERS, BY COUNTRY, 2024–2031 (USD MILLION) 157 TABLE 132 ASIA PACIFIC: CARDIAC MARKER TESTING MARKET FOR OTHER CARDIAC BIOMARKERS, BY COUNTRY, 2024–2031 (USD MILLION) 157 TABLE 133 LATIN AMERICA: CARDIAC MARKER TESTING MARKET FOR OTHER CARDIAC BIOMARKERS, BY COUNTRY, 2024–2031 (USD MILLION) 158 TABLE 134 US: CARDIAC MARKER TESTING MARKET, BY BIOMARKER TYPE, 2024–2031 (MILLION UNITS) 159 TABLE 135 CANADA: CARDIAC MARKER TESTING MARKET, BY BIOMARKER TYPE, 2024–2031 (MILLION UNITS) 159 TABLE 136 GERMANY: CARDIAC MARKER TESTING MARKET, BY BIOMARKER TYPE, 2024–2031 (MILLION UNITS) 160 TABLE 137 UK: CARDIAC MARKER TESTING MARKET, BY BIOMARKER TYPE, 2024–2031 (MILLION UNITS) 160 TABLE 138 FRANCE: CARDIAC MARKER TESTING MARKET, BY BIOMARKER TYPE, 2024–2031 (MILLION UNITS) 161 TABLE 139 ITALY: CARDIAC MARKER TESTING MARKET, BY BIOMARKER TYPE, 2024–2031 (MILLION UNITS) 161 TABLE 140 SPAIN: CARDIAC MARKER TESTING MARKET, BY BIOMARKER TYPE, 2024–2031 (MILLION UNITS) 162 TABLE 141 CHINA: CARDIAC MARKER TESTING MARKET, BY BIOMARKER TYPE, 2024–2031 (MILLION UNITS) 162 TABLE 142 JAPAN: CARDIAC MARKER TESTING MARKET, BY BIOMARKER TYPE, 2024–2031 (MILLION UNITS) 163 TABLE 143 INDIA: CARDIAC MARKER TESTING MARKET, BY BIOMARKER TYPE, 2024–2031 (MILLION UNITS) 163 TABLE 144 BRAZIL: CARDIAC MARKER TESTING MARKET, BY BIOMARKER TYPE, 2024–2031 (MILLION UNITS) 164 TABLE 145 MEXICO: CARDIAC MARKER TESTING MARKET, BY BIOMARKER TYPE, 2024–2031 (MILLION UNITS) 164 TABLE 146 CARDIAC MARKER TESTING MARKET, BY POINT OF TESTING, 2024–2031 (USD MILLION) 166 TABLE 147 CARDIAC MARKER TESTING MARKET FOR LAB TESTS, BY REGION, 2024–2031 (USD MILLION) 167 TABLE 148 NORTH AMERICA: CARDIAC MARKER TESTING MARKET FOR LAB TESTS, BY COUNTRY, 2024–2031 (USD MILLION) 167 TABLE 149 EUROPE: CARDIAC MARKER TESTING MARKET FOR LAB TESTS, BY COUNTRY, 2024–2031 (USD MILLION) 168 TABLE 150 ASIA PACIFIC: CARDIAC MARKER TESTING MARKET FOR LAB TESTS, BY COUNTRY, 2024–2031 (USD MILLION) 168 TABLE 151 LATIN AMERICA: CARDIAC MARKER TESTING MARKET FOR LAB TESTS, BY COUNTRY, 2024–2031 (USD MILLION) 169 TABLE 152 CARDIAC MARKER TESTING MARKET FOR POC TESTS, BY REGION, 2024–2031 (USD MILLION) 170 TABLE 153 NORTH AMERICA: CARDIAC MARKER TESTING MARKET FOR POC TESTS, BY COUNTRY, 2024–2031 (USD MILLION) 170 TABLE 154 EUROPE: CARDIAC MARKER TESTING MARKET FOR POC TESTS, BY COUNTRY, 2024–2031 (USD MILLION) 170 TABLE 155 ASIA PACIFIC: CARDIAC MARKER TESTING MARKET FOR POC TESTS, BY COUNTRY, 2024–2031 (USD MILLION) 171 TABLE 156 LATIN AMERICA: CARDIAC MARKER TESTING MARKET FOR POC TESTS, BY COUNTRY, 2024–2031 (USD MILLION) 171 TABLE 157 CARDIAC MARKER TESTING MARKET, BY ASSAY FORMAT, 2024–2031 (USD MILLION) 173 TABLE 158 CARDIAC MARKER TESTING MARKET FOR SINGLEPLEX ASSAYS, BY REGION, 2024–2031 (USD MILLION) 174 TABLE 159 NORTH AMERICA: CARDIAC MARKER TESTING MARKET FOR SINGLEPLEX ASSAYS, BY COUNTRY, 2024–2031 (USD MILLION) 174 TABLE 160 EUROPE: CARDIAC MARKER TESTING MARKET FOR SINGLEPLEX ASSAYS, BY COUNTRY, 2024–2031 (USD MILLION) 174 TABLE 161 ASIA PACIFIC: CARDIAC MARKER TESTING MARKET FOR SINGLEPLEX ASSAYS, BY COUNTRY, 2024–2031 (USD MILLION) 175 TABLE 162 LATIN AMERICA: CARDIAC MARKER TESTING MARKET FOR SINGLEPLEX ASSAYS, BY COUNTRY, 2024–2031 (USD MILLION) 175 TABLE 163 CARDIAC MARKER TESTING MARKET FOR MULTIPLEX ASSAYS, BY REGION, 2024–2031 (USD MILLION) 176 TABLE 164 NORTH AMERICA: CARDIAC MARKER TESTING MARKET FOR MULTIPLEX ASSAYS, BY COUNTRY, 2024–2031 (USD MILLION) 176 TABLE 165 EUROPE: CARDIAC MARKER TESTING MARKET FOR MULTIPLEX ASSAYS, BY COUNTRY, 2024–2031 (USD MILLION) 177 TABLE 166 ASIA PACIFIC: CARDIAC MARKER TESTING MARKET FOR MULTIPLEX ASSAYS, BY COUNTRY, 2024–2031 (USD MILLION) 177 TABLE 167 LATIN AMERICA: CARDIAC MARKER TESTING MARKET FOR MULTIPLEX ASSAYS, BY COUNTRY, 2024–2031 (USD MILLION) 178 TABLE 168 CARDIAC MARKER TESTING MARKET, BY END USER, 2024–2031 (USD MILLION) 180 TABLE 169 CARDIAC MARKER TESTING MARKET FOR LABORATORY TESTING FACILITIES, BY TYPE, 2024–2031 (USD MILLION) 181 TABLE 170 CARDIAC MARKER TESTING MARKET FOR LABORATORY TESTING FACILITIES, BY REGION, 2024–2031 (USD MILLION) 181 TABLE 171 NORTH AMERICA: CARDIAC MARKER TESTING MARKET FOR LABORATORY TESTING FACILITIES, BY COUNTRY, 2024–2031 (USD MILLION) 182 TABLE 172 EUROPE: CARDIAC MARKER TESTING MARKET FOR LABORATORY TESTING FACILITIES, BY COUNTRY, 2024–2031 (USD MILLION) 182 TABLE 173 ASIA PACIFIC: CARDIAC MARKER TESTING MARKET FOR LABORATORY TESTING FACILITIES, BY COUNTRY, 2024–2031 (USD MILLION) 183 TABLE 174 LATIN AMERICA: CARDIAC MARKER TESTING MARKET FOR LABORATORY TESTING FACILITIES, BY COUNTRY, 2024–2031 (USD MILLION) 183 TABLE 175 CARDIAC MARKER TESTING MARKET FOR HOSPITAL LABORATORIES, BY REGION, 2024–2031 (USD MILLION) 184 TABLE 176 NORTH AMERICA: CARDIAC MARKER TESTING MARKET FOR HOSPITAL LABORATORIES, BY COUNTRY, 2024–2031 (USD MILLION) 185 TABLE 177 EUROPE: CARDIAC MARKER TESTING MARKET FOR HOSPITAL LABORATORIES, BY COUNTRY, 2024–2031 (USD MILLION) 185 TABLE 178 ASIA PACIFIC: CARDIAC MARKER TESTING MARKET FOR HOSPITAL LABORATORIES, BY COUNTRY, 2024–2031 (USD MILLION) 186 TABLE 179 LATIN AMERICA: CARDIAC MARKER TESTING MARKET FOR HOSPITAL LABORATORIES, BY COUNTRY, 2024–2031 (USD MILLION) 186 TABLE 180 CARDIAC MARKER TESTING MARKET FOR REFERENCE LABORATORIES, BY REGION, 2024–2031 (USD MILLION) 187 TABLE 181 NORTH AMERICA: CARDIAC MARKER TESTING MARKET FOR REFERENCE LABORATORIES, BY COUNTRY, 2024–2031 (USD MILLION) 187 TABLE 182 EUROPE: CARDIAC MARKER TESTING MARKET FOR REFERENCE LABORATORIES, BY COUNTRY, 2024–2031 (USD MILLION) 188 TABLE 183 ASIA PACIFIC: CARDIAC MARKER TESTING MARKET FOR REFERENCE LABORATORIES, BY COUNTRY, 2024–2031 (USD MILLION) 188 TABLE 184 LATIN AMERICA: CARDIAC MARKER TESTING MARKET FOR REFERENCE LABORATORIES, BY COUNTRY, 2024–2031 (USD MILLION) 189 TABLE 185 CARDIAC MARKER TESTING MARKET FOR CONTRACT TESTING LABORATORIES, BY REGION, 2024–2031 (USD MILLION) 190 TABLE 186 NORTH AMERICA: CARDIAC MARKER TESTING MARKET FOR CONTRACT TESTING LABORATORIES, BY COUNTRY, 2024–2031 (USD MILLION) 190 TABLE 187 EUROPE: CARDIAC MARKER TESTING MARKET FOR CONTRACT TESTING LABORATORIES, BY COUNTRY, 2024–2031 (USD MILLION) 190 TABLE 188 ASIA PACIFIC: CARDIAC MARKER TESTING MARKET FOR CONTRACT TESTING LABORATORIES, BY COUNTRY, 2024–2031 (USD MILLION) 191 TABLE 189 LATIN AMERICA: CARDIAC MARKER TESTING MARKET FOR CONTRACT TESTING LABORATORIES, BY COUNTRY, 2024–2031 (USD MILLION) 191 TABLE 190 CARDIAC MARKER TESTING MARKET FOR ACADEMIC INSTITUTES, BY REGION, 2024–2031 (USD MILLION) 192 TABLE 191 NORTH AMERICA: CARDIAC MARKER TESTING MARKET FOR ACADEMIC INSTITUTES, BY COUNTRY, 2024–2031 (USD MILLION) 192 TABLE 192 EUROPE: CARDIAC MARKER TESTING MARKET FOR ACADEMIC INSTITUTES, BY COUNTRY, 2024–2031 (USD MILLION) 193 TABLE 193 ASIA PACIFIC: CARDIAC MARKER TESTING MARKET FOR ACADEMIC INSTITUTES, BY COUNTRY, 2024–2031 (USD MILLION) 193 TABLE 194 LATIN AMERICA: CARDIAC MARKER TESTING MARKET FOR ACADEMIC INSTITUTES, BY COUNTRY, 2024–2031 (USD MILLION) 194 TABLE 195 CARDIAC MARKER TESTING MARKET FOR POINT-OF-CARE TESTING, BY REGION, 2024–2031 (USD MILLION) 195 TABLE 196 NORTH AMERICA: CARDIAC MARKER TESTING MARKET FOR POINT-OF-CARE TESTING, BY COUNTRY, 2024–2031 (USD MILLION) 195 TABLE 197 EUROPE: CARDIAC MARKER TESTING MARKET FOR POINT-OF-CARE TESTING, BY COUNTRY, 2024–2031 (USD MILLION) 195 TABLE 198 ASIA PACIFIC: CARDIAC MARKER TESTING MARKET FOR POINT-OF-CARE TESTING, BY COUNTRY, 2024–2031 (USD MILLION) 196 TABLE 199 LATIN AMERICA: CARDIAC MARKER TESTING MARKET FOR POINT-OF-CARE TESTING, BY COUNTRY, 2024–2031 (USD MILLION) 196 TABLE 200 CARDIAC MARKER TESTING MARKET, BY REGION, 2024–2031 (USD MILLION) 198 TABLE 201 NORTH AMERICA: CARDIAC MARKER TESTING MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 199 TABLE 202 NORTH AMERICA: CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 200 TABLE 203 NORTH AMERICA: CARDIAC MARKER TESTING MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 200 TABLE 204 NORTH AMERICA: CARDIAC MARKER TESTING MARKET FOR IMMUNOASSAYS, BY TYPE, 2024–2031 (USD MILLION) 200 TABLE 205 NORTH AMERICA: CARDIAC MARKER TESTING MARKET, BY INDICATION, 2024–2031 (USD MILLION) 201 TABLE 206 NORTH AMERICA: CARDIAC MARKER TESTING MARKET, BY BIOMARKER TYPE, 2024–2031 (USD MILLION) 201 TABLE 207 NORTH AMERICA: CARDIAC MARKER TESTING MARKET, BY POINT OF TESTING, 2024–2031 (USD MILLION) 202 TABLE 208 NORTH AMERICA: CARDIAC MARKER TESTING MARKET, BY ASSAY FORMAT, 2024–2031 (USD MILLION) 202 TABLE 209 NORTH AMERICA: CARDIAC MARKER TESTING MARKET, BY END USER, 2024–2031 (USD MILLION) 202 TABLE 210 NORTH AMERICA: CARDIAC MARKER TESTING MARKET FOR LABORATORY TESTING FACILITIES, BY TYPE, 2024–2031 (USD MILLION) 203 TABLE 211 US: CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 204 TABLE 212 US: CARDIAC MARKER TESTING MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 204 TABLE 213 US: CARDIAC MARKER TESTING MARKET FOR IMMUNOASSAYS, BY TYPE, 2024–2031 (USD MILLION) 204 TABLE 214 US: CARDIAC MARKER TESTING MARKET, BY INDICATION, 2024–2031 (USD MILLION) 205 TABLE 215 US: CARDIAC MARKER TESTING MARKET, BY BIOMARKER TYPE, 2024–2031 (USD MILLION) 205 TABLE 216 US: CARDIAC MARKER TESTING MARKET, BY POINT OF TESTING, 2024–2031 (USD MILLION) 206 TABLE 217 US: CARDIAC MARKER TESTING MARKET, BY ASSAY FORMAT, 2024–2031 (USD MILLION) 206 TABLE 218 US: CARDIAC MARKER TESTING MARKET, BY END USER, 2024–2031 (USD MILLION) 206 TABLE 219 US: CARDIAC MARKER TESTING MARKET FOR LABORATORY TESTING FACILITIES, BY TYPE, 2024–2031 (USD MILLION) 207 TABLE 220 CANADA: CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 208 TABLE 221 CANADA: CARDIAC MARKER TESTING MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 208 TABLE 222 CANADA: CARDIAC MARKER TESTING MARKET FOR IMMUNOASSAYS, BY TYPE, 2024–2031 (USD MILLION) 208 TABLE 223 CANADA: CARDIAC MARKER TESTING MARKET, BY INDICATION, 2024–2031 (USD MILLION) 209 TABLE 224 CANADA: CARDIAC MARKER TESTING MARKET, BY BIOMARKER TYPE, 2024–2031 (USD MILLION) 209 TABLE 225 CANADA: CARDIAC MARKER TESTING MARKET, BY POINT OF TESTING, 2024–2031 (USD MILLION) 210 TABLE 226 CANADA: CARDIAC MARKER TESTING MARKET, BY ASSAY FORMAT, 2024–2031 (USD MILLION) 210 TABLE 227 CANADA: CARDIAC MARKER TESTING MARKET, BY END USER, 2024–2031 (USD MILLION) 210 TABLE 228 CANADA: CARDIAC MARKER TESTING MARKET FOR LABORATORY TESTING FACILITIES, BY TYPE, 2024–2031 (USD MILLION) 211 TABLE 229 EUROPE: CARDIAC MARKER TESTING MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 211 TABLE 230 EUROPE: CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 212 TABLE 231 EUROPE: CARDIAC MARKER TESTING MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 212 TABLE 232 EUROPE: CARDIAC MARKER TESTING MARKET FOR IMMUNOASSAYS, BY TYPE, 2024–2031 (USD MILLION) 212 TABLE 233 EUROPE: CARDIAC MARKER TESTING MARKET, BY INDICATION, 2024–2031 (USD MILLION) 213 TABLE 234 EUROPE: CARDIAC MARKER TESTING MARKET, BY BIOMARKER TYPE, 2024–2031 (USD MILLION) 213 TABLE 235 EUROPE: CARDIAC MARKER TESTING MARKET, BY POINT OF TESTING, 2024–2031 (USD MILLION) 214 TABLE 236 EUROPE: CARDIAC MARKER TESTING MARKET, BY ASSAY FORMAT, 2024–2031 (USD MILLION) 214 TABLE 237 EUROPE: CARDIAC MARKER TESTING MARKET, BY END USER, 2024–2031 (USD MILLION) 214 TABLE 238 EUROPE: CARDIAC MARKER TESTING MARKET FOR LABORATORY TESTING FACILITIES, BY TYPE, 2024–2031 (USD MILLION) 215 TABLE 239 GERMANY: CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 216 TABLE 240 GERMANY: CARDIAC MARKER TESTING MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 216 TABLE 241 GERMANY: CARDIAC MARKER TESTING MARKET FOR IMMUNOASSAYS, BY TYPE, 2024–2031 (USD MILLION) 216 TABLE 242 GERMANY: CARDIAC MARKER TESTING MARKET, BY INDICATION, 2024–2031 (USD MILLION) 217 TABLE 243 GERMANY: CARDIAC MARKER TESTING MARKET, BY BIOMARKER TYPE, 2024–2031 (USD MILLION) 217 TABLE 244 GERMANY: CARDIAC MARKER TESTING MARKET, BY POINT OF TESTING, 2024–2031 (USD MILLION) 218 TABLE 245 GERMANY: CARDIAC MARKER TESTING MARKET, BY ASSAY FORMAT, 2024–2031 (USD MILLION) 218 TABLE 246 GERMANY: CARDIAC MARKER TESTING MARKET, BY END USER, 2024–2031 (USD MILLION) 218 TABLE 247 GERMANY: CARDIAC MARKER TESTING MARKET FOR LABORATORY TESTING FACILITIES, BY TYPE, 2024–2031 (USD MILLION) 219 TABLE 248 UK: CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 219 TABLE 249 UK: CARDIAC MARKER TESTING MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 220 TABLE 250 UK: CARDIAC MARKER TESTING MARKET FOR IMMUNOASSAYS, BY TYPE, 2024–2031 (USD MILLION) 220 TABLE 251 UK: CARDIAC MARKER TESTING MARKET, BY INDICATION, 2024–2031 (USD MILLION) 220 TABLE 252 UK: CARDIAC MARKER TESTING MARKET, BY BIOMARKER TYPE, 2024–2031 (USD MILLION) 221 TABLE 253 UK: CARDIAC MARKER TESTING MARKET, BY POINT OF TESTING, 2024–2031 (USD MILLION) 221 TABLE 254 UK: CARDIAC MARKER TESTING MARKET, BY ASSAY FORMAT, 2024–2031 (USD MILLION) 221 TABLE 255 UK: CARDIAC MARKER TESTING MARKET, BY END USER, 2024–2031 (USD MILLION) 222 TABLE 256 UK: CARDIAC MARKER TESTING MARKET FOR LABORATORY TESTING FACILITIES, BY TYPE, 2024–2031 (USD MILLION) 222 TABLE 257 FRANCE: CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 223 TABLE 258 FRANCE: CARDIAC MARKER TESTING MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 223 TABLE 259 FRANCE: CARDIAC MARKER TESTING MARKET FOR IMMUNOASSAYS, BY TYPE, 2024–2031 (USD MILLION) 223 TABLE 260 FRANCE: CARDIAC MARKER TESTING MARKET, BY INDICATION, 2024–2031 (USD MILLION) 224 TABLE 261 FRANCE: CARDIAC MARKER TESTING MARKET, BY BIOMARKER TYPE, 2024–2031 (USD MILLION) 224 TABLE 262 FRANCE: CARDIAC MARKER TESTING MARKET, BY POINT OF TESTING, 2024–2031 (USD MILLION) 225 TABLE 263 FRANCE: CARDIAC MARKER TESTING MARKET, BY ASSAY FORMAT, 2024–2031 (USD MILLION) 225 TABLE 264 FRANCE: CARDIAC MARKER TESTING MARKET, BY END USER, 2024–2031 (USD MILLION) 225 TABLE 265 FRANCE: CARDIAC MARKER TESTING MARKET FOR LABORATORY TESTING FACILITIES, BY TYPE, 2024–2031 (USD MILLION) 226 TABLE 266 ITALY: CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 227 TABLE 267 ITALY: CARDIAC MARKER TESTING MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 227 TABLE 268 ITALY: CARDIAC MARKER TESTING MARKET FOR IMMUNOASSAYS, BY TYPE, 2024–2031 (USD MILLION) 227 TABLE 269 ITALY: CARDIAC MARKER TESTING MARKET, BY INDICATION, 2024–2031 (USD MILLION) 228 TABLE 270 ITALY: CARDIAC MARKER TESTING MARKET, BY BIOMARKER TYPE, 2024–2031 (USD MILLION) 228 TABLE 271 ITALY: CARDIAC MARKER TESTING MARKET, BY POINT OF TESTING, 2024–2031 (USD MILLION) 229 TABLE 272 ITALY: CARDIAC MARKER TESTING MARKET, BY ASSAY FORMAT, 2024–2031 (USD MILLION) 229 TABLE 273 ITALY: CARDIAC MARKER TESTING MARKET, BY END USER, 2024–2031 (USD MILLION) 229 TABLE 274 ITALY: CARDIAC MARKER TESTING MARKET FOR LABORATORY TESTING FACILITIES, BY TYPE, 2024–2031 (USD MILLION) 230 TABLE 275 SPAIN: CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 231 TABLE 276 SPAIN: CARDIAC MARKER TESTING MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 231 TABLE 277 SPAIN: CARDIAC MARKER TESTING MARKET FOR IMMUNOASSAYS, BY TYPE, 2024–2031 (USD MILLION) 231 TABLE 278 SPAIN: CARDIAC MARKER TESTING MARKET, BY INDICATION, 2024–2031 (USD MILLION) 232 TABLE 279 SPAIN: CARDIAC MARKER TESTING MARKET, BY BIOMARKER TYPE, 2024–2031 (USD MILLION) 232 TABLE 280 SPAIN: CARDIAC MARKER TESTING MARKET, BY POINT OF TESTING, 2024–2031 (USD MILLION) 233 TABLE 281 SPAIN: CARDIAC MARKER TESTING MARKET, BY ASSAY FORMAT, 2024–2031 (USD MILLION) 233 TABLE 282 SPAIN: CARDIAC MARKER TESTING MARKET, BY END USER, 2024–2031 (USD MILLION) 233 TABLE 283 SPAIN: CARDIAC MARKER TESTING MARKET FOR LABORATORY TESTING FACILITIES, BY TYPE, 2024–2031 (USD MILLION) 234 TABLE 284 REST OF EUROPE: CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 235 TABLE 285 REST OF EUROPE: CARDIAC MARKER TESTING MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 235 TABLE 286 REST OF EUROPE: CARDIAC MARKER TESTING MARKET FOR IMMUNOASSAYS, BY TYPE, 2024–2031 (USD MILLION) 235 TABLE 287 REST OF EUROPE: CARDIAC MARKER TESTING MARKET, BY INDICATION, 2024–2031 (USD MILLION) 236 TABLE 288 REST OF EUROPE: CARDIAC MARKER TESTING MARKET, BY BIOMARKER TYPE, 2024–2031 (USD MILLION) 236 TABLE 289 REST OF EUROPE: CARDIAC MARKER TESTING MARKET, BY POINT OF TESTING, 2024–2031 (USD MILLION) 237 TABLE 290 REST OF EUROPE: CARDIAC MARKER TESTING MARKET, BY ASSAY FORMAT, 2024–2031 (USD MILLION) 237 TABLE 291 REST OF EUROPE: CARDIAC MARKER TESTING MARKET, BY END USER, 2024–2031 (USD MILLION) 237 TABLE 292 REST OF EUROPE: CARDIAC MARKER TESTING MARKET FOR LABORATORY TESTING FACILITIES, BY TYPE, 2024–2031 (USD MILLION) 238 TABLE 293 ASIA PACIFIC: CARDIAC MARKER TESTING MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 239 TABLE 294 ASIA PACIFIC: CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 240 TABLE 295 ASIA PACIFIC: CARDIAC MARKER TESTING MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 240 TABLE 296 ASIA PACIFIC: CARDIAC MARKER TESTING MARKET FOR IMMUNOASSAYS, BY TYPE, 2024–2031 (USD MILLION) 240 TABLE 297 ASIA PACIFIC: CARDIAC MARKER TESTING MARKET, BY INDICATION, 2024–2031 (USD MILLION) 241 TABLE 298 ASIA PACIFIC: CARDIAC MARKER TESTING MARKET, BY BIOMARKER TYPE, 2024–2031 (USD MILLION) 241 TABLE 299 ASIA PACIFIC: CARDIAC MARKER TESTING MARKET, BY POINT OF TESTING, 2024–2031 (USD MILLION) 242 TABLE 300 ASIA PACIFIC: CARDIAC MARKER TESTING MARKET, BY ASSAY FORMAT, 2024–2031 (USD MILLION) 242 TABLE 301 ASIA PACIFIC: CARDIAC MARKER TESTING MARKET, BY END USER, 2024–2031 (USD MILLION) 242 TABLE 302 ASIA PACIFIC: CARDIAC MARKER TESTING MARKET FOR LABORATORY TESTING FACILITIES, BY TYPE, 2024–2031 (USD MILLION) 243 TABLE 303 JAPAN: CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 244 TABLE 304 JAPAN: CARDIAC MARKER TESTING MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 244 TABLE 305 JAPAN: CARDIAC MARKER TESTING MARKET FOR IMMUNOASSAYS, BY TYPE, 2024–2031 (USD MILLION) 244 TABLE 306 JAPAN: CARDIAC MARKER TESTING MARKET, BY INDICATION, 2024–2031 (USD MILLION) 245 TABLE 307 JAPAN: CARDIAC MARKER TESTING MARKET, BY BIOMARKER TYPE, 2024–2031 (USD MILLION) 245 TABLE 308 JAPAN: CARDIAC MARKER TESTING MARKET, BY POINT OF TESTING, 2024–2031 (USD MILLION) 246 TABLE 309 JAPAN: CARDIAC MARKER TESTING MARKET, BY ASSAY FORMAT, 2024–2031 (USD MILLION) 246 TABLE 310 JAPAN: CARDIAC MARKER TESTING MARKET, BY END USER, 2024–2031 (USD MILLION) 246 TABLE 311 JAPAN: CARDIAC MARKER TESTING MARKET FOR LABORATORY TESTING FACILITIES, BY TYPE, 2024–2031 (USD MILLION) 247 TABLE 312 CHINA: CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 248 TABLE 313 CHINA: CARDIAC MARKER TESTING MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 248 TABLE 314 CHINA: CARDIAC MARKER TESTING MARKET FOR IMMUNOASSAYS, BY TYPE, 2024–2031 (USD MILLION) 248 TABLE 315 CHINA: CARDIAC MARKER TESTING MARKET, BY INDICATION, 2024–2031 (USD MILLION) 249 TABLE 316 CHINA: CARDIAC MARKER TESTING MARKET, BY BIOMARKER TYPE, 2024–2031 (USD MILLION) 249 TABLE 317 CHINA: CARDIAC MARKER TESTING MARKET, BY POINT OF TESTING, 2024–2031 (USD MILLION) 250 TABLE 318 CHINA: CARDIAC MARKER TESTING MARKET, BY ASSAY FORMAT, 2024–2031 (USD MILLION) 250 TABLE 319 CHINA: CARDIAC MARKER TESTING MARKET, BY END USER, 2024–2031 (USD MILLION) 250 TABLE 320 CHINA: CARDIAC MARKER TESTING MARKET FOR LABORATORY TESTING FACILITIES, BY TYPE, 2024–2031 (USD MILLION) 251 TABLE 321 INDIA: CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 252 TABLE 322 INDIA: CARDIAC MARKER TESTING MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 252 TABLE 323 INDIA: CARDIAC MARKER TESTING MARKET FOR IMMUNOASSAYS, BY TYPE, 2024–2031 (USD MILLION) 252 TABLE 324 INDIA: CARDIAC MARKER TESTING MARKET, BY INDICATION, 2024–2031 (USD MILLION) 253 TABLE 325 INDIA: CARDIAC MARKER TESTING MARKET, BY BIOMARKER TYPE, 2024–2031 (USD MILLION) 253 TABLE 326 INDIA: CARDIAC MARKER TESTING MARKET, BY POINT OF TESTING, 2024–2031 (USD MILLION) 254 TABLE 327 INDIA: CARDIAC MARKER TESTING MARKET, BY ASSAY FORMAT, 2024–2031 (USD MILLION) 254 TABLE 328 INDIA: CARDIAC MARKER TESTING MARKET, BY END USER, 2024–2031 (USD MILLION) 254 TABLE 329 INDIA: CARDIAC MARKER TESTING MARKET FOR LABORATORY TESTING FACILITIES, BY TYPE, 2024–2031 (USD MILLION) 255 TABLE 330 AUSTRALIA: CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 255 TABLE 331 AUSTRALIA: CARDIAC MARKER TESTING MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 256 TABLE 332 AUSTRALIA: CARDIAC MARKER TESTING MARKET FOR IMMUNOASSAYS, BY TYPE, 2024–2031 (USD MILLION) 256 TABLE 333 AUSTRALIA: CARDIAC MARKER TESTING MARKET, BY INDICATION, 2024–2031 (USD MILLION) 256 TABLE 334 AUSTRALIA: CARDIAC MARKER TESTING MARKET, BY BIOMARKER TYPE, 2024–2031 (USD MILLION) 257 TABLE 335 AUSTRALIA: CARDIAC MARKER TESTING MARKET, BY POINT OF TESTING, 2024–2031 (USD MILLION) 257 TABLE 336 AUSTRALIA: CARDIAC MARKER TESTING MARKET, BY ASSAY FORMAT, 2024–2031 (USD MILLION) 257 TABLE 337 AUSTRALIA: CARDIAC MARKER TESTING MARKET, BY END USER, 2024–2031 (USD MILLION) 258 TABLE 338 AUSTRALIA: CARDIAC MARKER TESTING MARKET FOR LABORATORY TESTING FACILITIES, BY TYPE, 2024–2031 (USD MILLION) 258 TABLE 339 SOUTH KOREA: CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 259 TABLE 340 SOUTH KOREA: CARDIAC MARKER TESTING MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 259 TABLE 341 SOUTH KOREA: CARDIAC MARKER TESTING MARKET FOR IMMUNOASSAY, BY TYPE, 2024–2031 (USD MILLION) 259 TABLE 342 SOUTH KOREA: CARDIAC MARKER TESTING MARKET, BY INDICATION, 2024–2031 (USD MILLION) 260 TABLE 343 SOUTH KOREA: CARDIAC MARKER TESTING MARKET, BY BIOMARKER TYPE, 2024–2031 (USD MILLION) 260 TABLE 344 SOUTH KOREA: CARDIAC MARKER TESTING MARKET, BY POINT OF TESTING, 2024–2031 (USD MILLION) 261 TABLE 345 SOUTH KOREA: CARDIAC MARKER TESTING MARKET, BY ASSAY FORMAT, 2024–2031 (USD MILLION) 261 TABLE 346 SOUTH KOREA: CARDIAC MARKER TESTING MARKET, BY END USER, 2024–2031 (USD MILLION) 261 TABLE 347 SOUTH KOREA: CARDIAC MARKER TESTING MARKET FOR LABORATORY TESTING FACILITIES, BY TYPE, 2024–2031 (USD MILLION) 262 TABLE 348 REST OF ASIA PACIFIC: CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 262 TABLE 349 REST OF ASIA PACIFIC: CARDIAC MARKER TESTING MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 263 TABLE 350 REST OF ASIA PACIFIC: CARDIAC MARKER TESTING MARKET FOR IMMUNOASSAYS, BY TYPE, 2024–2031 (USD MILLION) 263 TABLE 351 REST OF ASIA PACIFIC: CARDIAC MARKER TESTING MARKET, BY INDICATION, 2024–2031 (USD MILLION) 263 TABLE 352 REST OF ASIA PACIFIC: CARDIAC MARKER TESTING MARKET, BY BIOMARKER TYPE, 2024–2031 (USD MILLION) 264 TABLE 353 REST OF ASIA PACIFIC: CARDIAC MARKER TESTING MARKET, BY POINT OF TESTING, 2024–2031 (USD MILLION) 264 TABLE 354 REST OF ASIA PACIFIC: CARDIAC MARKER TESTING MARKET, BY ASSAY FORMAT, 2024–2031 (USD MILLION) 264 TABLE 355 REST OF ASIA PACIFIC: CARDIAC MARKER TESTING MARKET, BY END USER, 2024–2031 (USD MILLION) 265 TABLE 356 REST OF ASIA PACIFIC: CARDIAC MARKER TESTING MARKET FOR LABORATORY TESTING FACILITIES, BY TYPE, 2024–2031 (USD MILLION) 265 TABLE 357 LATIN AMERICA: CARDIAC MARKER TESTING MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 266 TABLE 358 LATIN AMERICA: CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 266 TABLE 359 LATIN AMERICA: CARDIAC MARKER TESTING MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 266 TABLE 360 LATIN AMERICA: CARDIAC MARKER TESTING MARKET FOR IMMUNOASSAYS, BY TYPE, 2024–2031 (USD MILLION) 267 TABLE 361 LATIN AMERICA: CARDIAC MARKER TESTING MARKET, BY INDICATION, 2024–2031 (USD MILLION) 267 TABLE 362 LATIN AMERICA: CARDIAC MARKER TESTING MARKET, BY BIOMARKER TYPE, 2024–2031 (USD MILLION) 268 TABLE 363 LATIN AMERICA: CARDIAC MARKER TESTING MARKET, BY POINT OF TESTING, 2024–2031 (USD MILLION) 268 TABLE 364 LATIN AMERICA: CARDIAC MARKER TESTING MARKET, BY ASSAY FORMAT, 2024–2031 (USD MILLION) 268 TABLE 365 LATIN AMERICA: CARDIAC MARKER TESTING MARKET, BY END USER, 2024–2031 (USD MILLION) 269 TABLE 366 LATIN AMERICA: CARDIAC MARKER TESTING MARKET FOR LABORATORY TESTING FACILITIES, BY TYPE, 2024–2031 (USD MILLION) 269 TABLE 367 BRAZIL: CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 270 TABLE 368 BRAZIL: CARDIAC MARKER TESTING MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 270 TABLE 369 BRAZIL: CARDIAC MARKER TESTING MARKET FOR IMMUNOASSAYS, BY TYPE, 2024–2031 (USD MILLION) 270 TABLE 370 BRAZIL: CARDIAC MARKER TESTING MARKET, BY INDICATION, 2024–2031 (USD MILLION) 271 TABLE 371 BRAZIL: CARDIAC MARKER TESTING MARKET, BY BIOMARKER TYPE, 2024–2031 (USD MILLION) 271 TABLE 372 BRAZIL: CARDIAC MARKER TESTING MARKET, BY POINT OF TESTING, 2024–2031 (USD MILLION) 272 TABLE 373 BRAZIL: CARDIAC MARKER TESTING MARKET, BY ASSAY FORMAT, 2024–2031 (USD MILLION) 272 TABLE 374 BRAZIL: CARDIAC MARKER TESTING MARKET, BY END USER, 2024–2031 (USD MILLION) 272 TABLE 375 BRAZIL: CARDIAC MARKER TESTING MARKET FOR LABORATORY TESTING FACILITIES, BY TYPE, 2024–2031 (USD MILLION) 273 TABLE 376 MEXICO: CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 274 TABLE 377 MEXICO: CARDIAC MARKER TESTING MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 274 TABLE 378 MEXICO: CARDIAC MARKER TESTING MARKET FOR IMMUNOASSAYS, BY TYPE, 2024–2031 (USD MILLION) 274 TABLE 379 MEXICO: CARDIAC MARKER TESTING MARKET, BY INDICATION, 2024–2031 (USD MILLION) 275 TABLE 380 MEXICO: CARDIAC MARKER TESTING MARKET, BY BIOMARKER TYPE, 2024–2031 (USD MILLION) 275 TABLE 381 MEXICO: CARDIAC MARKER TESTING MARKET, BY POINT OF TESTING, 2024–2031 (USD MILLION) 276 TABLE 382 MEXICO: CARDIAC MARKER TESTING MARKET, BY ASSAY FORMAT, 2024–2031 (USD MILLION) 276 TABLE 383 MEXICO: CARDIAC MARKER TESTING MARKET, BY END USER, 2024–2031 (USD MILLION) 276 TABLE 384 MEXICO: CARDIAC MARKER TESTING MARKET FOR LABORATORY TESTING FACILITIES, BY TYPE, 2024–2031 (USD MILLION) 277 TABLE 385 REST OF LATIN AMERICA: CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 277 TABLE 386 REST OF LATIN AMERICA: CARDIAC MARKER TESTING MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 278 TABLE 387 REST OF LATIN AMERICA: CARDIAC MARKER TESTING MARKET FOR IMMUNOASSAY, BY TYPE, 2024–2031 (USD MILLION) 278 TABLE 388 REST OF LATIN AMERICA: CARDIAC MARKER TESTING MARKET, BY INDICATION, 2024–2031 (USD MILLION) 278 TABLE 389 REST OF LATIN AMERICA: CARDIAC MARKER TESTING MARKET, BY BIOMARKER TYPE, 2024–2031 (USD MILLION) 279 TABLE 390 REST OF LATIN AMERICA: CARDIAC MARKER TESTING MARKET, BY POINT OF TESTING, 2024–2031 (USD MILLION) 279 TABLE 391 REST OF LATIN AMERICA: CARDIAC MARKER TESTING MARKET, BY ASSAY FORMAT, 2024–2031 (USD MILLION) 279 TABLE 392 REST OF LATIN AMERICA: CARDIAC MARKER TESTING MARKET, BY END USER, 2024–2031 (USD MILLION) 280 TABLE 393 REST OF LATIN AMERICA: CARDIAC MARKER TESTING MARKET FOR LABORATORY TESTING FACILITIES, BY TYPE, 2024–2031 (USD MILLION) 280 TABLE 394 MIDDLE EAST & AFRICA: CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 281 TABLE 395 MIDDLE EAST & AFRICA: CARDIAC MARKER TESTING MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 281 TABLE 396 MIDDLE EAST & AFRICA: CARDIAC MARKER TESTING MARKET FOR IMMUNOASSAYS, BY TYPE, 2024–2031 (USD MILLION) 281 TABLE 397 MIDDLE EAST & AFRICA: CARDIAC MARKER TESTING MARKET, BY INDICATION, 2024–2031 (USD MILLION) 282 TABLE 398 MIDDLE EAST & AFRICA: CARDIAC MARKER TESTING MARKET, BY BIOMARKER TYPE, 2024–2031 (USD MILLION) 282 TABLE 399 MIDDLE EAST & AFRICA: CARDIAC MARKER TESTING MARKET, BY POINT OF TESTING, 2024–2031 (USD MILLION) 283 TABLE 400 MIDDLE EAST & AFRICA: CARDIAC MARKER TESTING MARKET, BY ASSAY FORMAT, 2024–2031 (USD MILLION) 283 TABLE 401 MIDDLE EAST & AFRICA: CARDIAC MARKER TESTING MARKET, BY END USER, 2024–2031 (USD MILLION) 283 TABLE 402 MIDDLE EAST & AFRICA: CARDIAC MARKER TESTING MARKET FOR LABORATORY TESTING FACILITIES, BY TYPE, 2024–2031 (USD MILLION) 284 TABLE 403 OVERVIEW OF STRATEGIES DEPLOYED BY KEY COMPANIES IN CARDIAC MARKER TESTING MARKET, JANUARY 2023−MARCH 2026 285 TABLE 404 CARDIAC MARKER TESTING MARKET: DEGREE OF COMPETITION 288 TABLE 405 CARDIAC MARKER TESTING MARKET: REGION FOOTPRINT 292 TABLE 406 CARDIAC MARKER TESTING MARKET: PRODUCT FOOTPRINT 293 TABLE 407 CARDIAC MARKER TESTING MARKET: TECHNOLOGY FOOTPRINT 293 TABLE 408 CARDIAC MARKER TESTING MARKET: POINT OF TESTING FOOTPRINT 294 TABLE 409 CARDIAC MARKER TESTING MARKET: DETAILED LIST OF KEY STARTUPS/SMES 296 TABLE 410 CARDIAC MARKER TESTING MARKET: COMPETITIVE BENCHMARKING OF STARTUPS/SMES (1/2) 296 TABLE 411 CARDIAC MARKER TESTING MARKET: COMPETITIVE BENCHMARKING OF STARTUPS/SMES (2/2) 297 TABLE 412 CARDIAC MARKER TESTING MARKET: PRODUCT APPROVALS, JANUARY 2023–JANUARY 2026 300 TABLE 413 CARDIAC MARKER TESTING MARKET: DEALS, JANUARY 2023–JANUARY 2026 300 TABLE 414 F. HOFFMANN-LA ROCHE AG: COMPANY OVERVIEW 302 TABLE 415 F. HOFFMANN-LA ROCHE AG: PRODUCTS OFFERED 303 TABLE 416 F. HOFFMANN-LA ROCHE AG: PRODUCT APPROVALS, JANUARY 2023–JANUARY 2026 305 TABLE 417 F. HOFFMANN-LA ROCHE AG: DEALS, JANUARY 2023–JANUARY 2026 305 TABLE 418 ABBOTT LABORATORIES: COMPANY OVERVIEW 307 TABLE 419 ABBOTT LABORATORIES: PRODUCTS OFFERED 308 TABLE 420 DANAHER CORPORATION: COMPANY OVERVIEW 310 TABLE 421 DANAHER CORPORATION: PRODUCTS OFFERED 311 TABLE 422 SIEMENS HEALTHINEERS AG: COMPANY OVERVIEW 313 TABLE 423 SIEMENS HEALTHINEERS AG: PRODUCTS OFFERED 314 TABLE 424 THERMO FISHER SCIENTIFIC: COMPANY OVERVIEW 317 TABLE 425 THERMO FISHER SCIENTIFIC: PRODUCTS OFFERED 318 TABLE 426 BIO-RAD LABORATORIES : COMPANY OVERVIEW 320 TABLE 427 BIO-RAD LABORATORIES : PRODUCTS OFFERED 321 TABLE 428 BIOMÉRIEUX SA : COMPANY OVERVIEW 322 TABLE 429 BIOMÉRIEUX SA : PRODUCTS OFFERED 323 TABLE 430 BIOMÉRIEUX SA: DEALS, JANUARY 2023–JANUARY 2026 324 TABLE 431 BECTON, DICKINSON AND COMPANY: COMPANY OVERVIEW 325 TABLE 432 BECTON, DICKINSON AND COMPANY: PRODUCTS OFFERED 326 TABLE 433 DIASORIN SPA: COMPANY OVERVIEW 327 TABLE 434 DIASORIN SPA: PRODUCTS OFFERED 328 TABLE 435 REVVITY: COMPANY OVERVIEW 329 TABLE 436 REVVITY: PRODUCTS OFFERED 331 TABLE 437 TOSOH CORPORATION: COMPANY OVERVIEW 332 TABLE 438 TOSOH CORPORATION: PRODUCTS OFFERED 333 TABLE 439 QUIDEL CORPORATION: COMPANY OVERVIEW 335 TABLE 440 QUIDEL CORPORATION: PRODUCTS OFFERED 336 TABLE 441 QUIDEL CORPORATION: PRODUCT APPROVALS, JANUARY 2023–JANUARY 2026 337 TABLE 442 QUIDEL CORPORATION: DEALS, JANUARY 2023–JANUARY 2026 337 TABLE 443 LSI MEDIENCE CORPORATION (PHC HOLDINGS CORPORATION): COMPANY OVERVIEW 338 TABLE 444 RANDOX LABORATORIES: COMPANY OVERVIEW 339 TABLE 445 GUANGZHOU WONDFO BIOTECH CO., LTD.: COMPANY OVERVIEW 340 TABLE 446 BODITECH MED INC.: COMPANY OVERVIEW 341 TABLE 447 BTNX INC.: COMPANY OVERVIEW 342 TABLE 448 RESPONSE BIOMEDICAL: COMPANY OVERVIEW 343 TABLE 449 ALFA SCIENTIFIC DESIGNS, INC.: COMPANY OVERVIEW 344 TABLE 450 CTK BIOTECH: COMPANY OVERVIEW 345 TABLE 451 CREATIVE DIAGNOSTICS: COMPANY OVERVIEW 346 TABLE 452 LIFESIGN LLC: COMPANY OVERVIEW 347 TABLE 453 DIASYS DIAGNOSTIC SYSTEMS GMBH: COMPANY OVERVIEW 348 TABLE 454 ATLAS MEDICAL GMBH: COMPANY OVERVIEW 349 TABLE 455 GETEIN BIOTECH INC.: COMPANY OVERVIEW 350 TABLE 456 STUDY ASSUMPTIONS 361 TABLE 457 CARDIAC MARKER TESTING MARKET: RISK ASSESSMENT 363 FIGURE 1 CARDIAC MARKER TESTING MARKET SEGMENTATION & REGIONAL SCOPE 36 FIGURE 2 KEY INSIGHTS & MARKET HIGHLIGHTS 40 FIGURE 3 GLOBAL CARDIAC MARKER TESTING MARKET, 2024–2031 40 FIGURE 4 MAJOR STRATEGIES ADOPTED BY KEY PLAYERS IN CARDIAC MARKER TESTING MARKET, 2023–2025 41 FIGURE 5 DISRUPTIVE TRENDS IMPACTING GROWTH OF CARDIAC MARKER TESTING MARKET 42 FIGURE 6 HIGH-GROWTH SEGMENTS & EMERGING FRONTIERS IN CARDIAC MARKER TESTING MARKET, 2025 43 FIGURE 7 ASIA PACIFIC TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD 44 FIGURE 8 RISING CASES OF CARDIOVASCULAR DISEASES TO DRIVE MARKET 45 FIGURE 9 REAGENTS & KITS SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD 45 FIGURE 10 IMMUNOASSAYS SEGMENT TO LEAD MARKET DURING FORECAST PERIOD 46 FIGURE 11 MYOCARDIAL INFARCTION SEGMENT TO LEAD MARKET DURING FORECAST PERIOD 46 FIGURE 12 TROPONIN I & T SEGMENT TO LEAD MARKET DURING FORECAST PERIOD 47 FIGURE 13 LAB TESTS SEGMENT TO LEAD MARKET DURING FORECAST PERIOD 47 FIGURE 14 SINGLEPLEX ASSAYS SEGMENT TO LEAD MARKET DURING FORECAST PERIOD 48 FIGURE 15 LABORATORY TESTING FACILITIES SEGMENT TO COMMAND LARGEST SHARE DURING FORECAST PERIOD 48 FIGURE 16 ASIA PACIFIC TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD 49 FIGURE 17 CARDIAC MARKER TESTING MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 50 FIGURE 18 CARDIAC MARKER TESTING MARKET: PORTER’S FIVE FORCES ANALYSIS 59 FIGURE 19 CARDIAC MARKER TESTING MARKET: SUPPLY CHAIN ANALYSIS 65 FIGURE 20 CARDIAC MARKER TESTING MARKET: VALUE CHAIN ANALYSIS 66 FIGURE 21 CARDIAC MARKER TESTING MARKET: ECOSYSTEM ANALYSIS 67 FIGURE 22 CARDIAC MARKER TESTING MARKET: TRENDS & DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 73 FIGURE 23 NUMBER OF DEALS & FUNDING ACTIVITIES IN CARDIAC MARKER TESTING MARKET 73 FIGURE 24 PATENT ANALYSIS FOR CARDIAC MARKER TESTING, JANUARY 2016–DECEMBER 2025 82 FIGURE 25 MARKET POTENTIAL OF AI IN CARDIAC MARKER TESTING MARKET 85 FIGURE 26 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY END USER 91 FIGURE 27 KEY BUYING CRITERIA, BY END USER 92 FIGURE 28 NORTH AMERICA: CARDIAC MARKER TESTING MARKET SNAPSHOT 199 FIGURE 29 ASIA PACIFIC: CARDIAC MARKER TESTING MARKET SNAPSHOT 239 FIGURE 30 REVENUE ANALYSIS OF KEY PLAYERS IN CARDIAC MARKER TESTING MARKET, 2023–2025 (USD MILLION) 287 FIGURE 31 CARDIAC MARKER TESTING MARKET SHARE ANALYSIS, 2025 (GLOBAL) 288 FIGURE 32 US: CARDIAC MARKER TESTING MARKET SHARE ANALYSIS, 2025 290 FIGURE 33 CARDIAC MARKER TESTING MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2025 291 FIGURE 34 CARDIAC MARKER TESTING MARKET: COMPANY FOOTPRINT 292 FIGURE 35 CARDIAC MARKER TESTING MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2025 295 FIGURE 36 EV/EBITDA OF KEY VENDORS 297 FIGURE 37 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS 298 FIGURE 38 CARDIAC MARKER TESTING MARKET: BRAND/PRODUCT COMPARISON FOR CARDIAC MARKER TESTING 299 FIGURE 39 F. HOFFMANN-LA ROCHE AG: COMPANY SNAPSHOT (2025) 303 FIGURE 40 ABBOTT LABORATORIES: COMPANY SNAPSHOT (2025) 308 FIGURE 41 DANAHER CORPORATION: COMPANY SNAPSHOT (2025) 311 FIGURE 42 SIEMENS HEALTHINEERS AG: COMPANY SNAPSHOT (2025) 314 FIGURE 43 THERMO FISHER SCIENTIFIC: COMPANY SNAPSHOT (2025) 318 FIGURE 44 BIO-RAD LABORATORIES : COMPANY SNAPSHOT (2025) 321 FIGURE 45 BIOMÉRIEUX SA : COMPANY SNAPSHOT (2025) 323 FIGURE 46 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT (2025) 326 FIGURE 47 DIASORIN SPA: COMPANY SNAPSHOT (2024) 328 FIGURE 48 REVVITY: COMPANY SNAPSHOT (2025) 330 FIGURE 49 TOSOH CORPORATION: COMPANY SNAPSHOT (2025) 333 FIGURE 50 QUIDEL CORPORATION: COMPANY SNAPSHOT (2025) 336 FIGURE 51 RESEARCH DESIGN 351 FIGURE 52 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION 357 FIGURE 53 TOP-DOWN APPROACH 359 FIGURE 54 DATA TRIANGULATION 360 FIGURE 55 PARAMETRIC ASSUMPTIONS 362